会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • LARGE ANIMAL MODEL FOR HUMAN-LIKE ADVANCED ATHEROSCLEROTIC PLAQUE
    • 人类先进的人体动物模型大动物模型
    • WO2010059391A1
    • 2010-05-27
    • PCT/US2009/062624
    • 2009-10-29
    • MEDTRONIC VASCULAR INC.TUNEV, StefanSHAH, AnkitCACERES, AlejandraGUO, YaTRUDEL, JulieHIM, PheanHEZI-YAMIT, Ayala
    • TUNEV, StefanSHAH, AnkitCACERES, AlejandraGUO, YaTRUDEL, JulieHIM, PheanHEZI-YAMIT, Ayala
    • A01K67/027A01K49/00
    • A01K67/027A01K2217/00A01K2227/108A01K2267/03A01K2267/0375
    • An animal model for cardiovascular disease comprising one or more vascular plaque lesions formed at selected sites within a vascular segment of a nonhuman mammal. The vascular plaque lesion is formed by administering a hypercholesterolemic diet to the nonhuman mammal, inflicting an injury to the vascular wall at the selected site after a predetermined exposure to the hypercholesterolemic diet, and applying a hydrogel to the injured vascular wall. Another aspect of the invention provides a method for evaluating a test compound for an effect on atherosclerotic lesion formation comprising administering to a nonhuman mammal a hypercholesterolemic diet, and, after a defined period of time, isolating a segment of a blood vessel using a balloon catheter, inflicting an injury to the vascular wall within the isolated segment, and applying a hydrogel within the vascular segment. The method further comprises forming a vascular plaque lesion on the vascular wall at the site of the injury, delivering the test compound to the nonhuman mammal, and monitoring atherosclerotic lesion size and composition at the injured site after a defined period of exposure to the test compound.
    • 一种用于心血管疾病的动物模型,其包含在非人哺乳动物的血管片段内的选定位置处形成的一个或多个血管斑块损伤。 通过向非人哺乳动物施用高胆固醇血症饮食来形成血管斑块损伤,在预先暴露于高胆固醇血症饮食之后对选定部位的血管壁施加损伤,并将水凝胶施加到损伤的血管壁。 本发明的另一方面提供了一种用于评估对动脉粥样硬化病变形成的影响的测试化合物的方法,包括向非人类哺乳动物施用高胆固醇血症饮食,并且在限定的时间段之后,使用气囊导管分离血管的一段 对隔离区段内的血管壁造成损伤,并在血管段内施用水凝胶。 该方法还包括在损伤部位的血管壁上形成血管斑块损伤,将测试化合物递送至非人类哺乳动物,并在暴露于测试化合物的确定的时间段后监测受伤部位的动脉粥样硬化病变大小和组成 。